ESR1 and breast cancer: Taking into consideration the two-fold gain in cytotoxicity of compound 4a against ERα-positive breast cancer cells vs. ERα-negative cells and its high activity as ERα inhibitor we performed immunoblotting of ERα in MCF-7 cells.